DAY & NITE
PHARMACY
🛒
☰
Home
/
Uncategorized
/ B&,L RENU MULTI PLUS 240ML””
B&,L RENU MULTI PLUS 240ML””
SKU:
7391899818900
Category:
Uncategorized
Description
Description
B&”
Related products
CETAPHIL MOIST CRM 453 FACE &, BODY””
Read more
Buy via WhatsApp
FACE BALM S/BERRY&,COCONUT HS””
Read more
Buy via WhatsApp
Search for:
Pages
#98 (no title)
Aiforia deal to expand access to pathology AI
Amphista doses first patient in AML trial of protein degrader
Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
Appointment
Astoriom acquires Sampled’s UK stability storage operations
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
AstraZeneca’s Trixeo approved in EU for asthma
AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
Bio-Techne opens GMP small-molecule manufacturing facility in Bristol
bit.bio expands human heart cell portfolio through myriamed partnership
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Bramacare opens supported-living facility for eating disorder recovery
Brenntag and dsm-firmenich expand biopharma vitamin partnership
Cart
CeramTec expands German production capacity for orthopaedic ceramics
Charity commits £800,000 to AI research into late breast cancer recurrence
Checkout
Claris reports visual acuity gains with experimental LSCD treatment
Contact us
Cori Clinical raises US$4m to expand AI platform for clinical trial design
Danish medical cannabis use rises as regulator reports no new safety signals
Daynite Pharmacy
Digital platform cuts pharmaceutical quality-record approval times by up to 90%
East London pharmacies pilot cholesterol-lowering injections to cut waiting times
Elementor #22
Elementor #75
ESTEVE CDMO adds $17.5m to Illinois expansion
Femtosecond laser cuts lung tumour margin assessment time
First 90 days of antipsychotic treatment linked to rapid metabolic changes
Global coalition calls for stronger government action on COPD
Home
Hot-tub therapy tested as potential treatment for peripheral artery disease
Migraine annual economic and quality-of-life burden in UK
Most advanced breast cancer patients treated in community settings, Phesi study finds
My account
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
NIHR chief scientific adviser visits Huddersfield health innovation campus
Ofichem acquires US drug substance CDMO Kinentia
One in three UK women with migraine say symptoms taken less seriously
Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
Pharmacy Services
Phoenix Labs acquires Kent Pharma
Refund and Returns Policy
Register Login user
Report highlights scope to expand day surgery
Shop
SMC accepts atogepant for acute migraine treatment in Scotland
Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia
Sterling doubles ADC manufacturing capacity at Welsh facility
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
Tridem begins phase Ib trial of Parkinson’s disease vaccine
UK immunoglobulin supply faces growing pressure, report warns
Welcome
Archives
September 2026
Categories
Uncategorized
(1)
💬